Cover Image
市場調查報告書

醫藥品主要企業系列:主要學名藥廠商 2017-2027

Pharma Leader Series: Top Generic Drug Producers Market Forecast 2017-2027: North America, Europe, India, Japan, South Africa, MENA

出版商 Visiongain Ltd 商品編碼 335356
出版日期 內容資訊 英文 214 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
醫藥品主要企業系列:主要學名藥廠商 2017-2027 Pharma Leader Series: Top Generic Drug Producers Market Forecast 2017-2027: North America, Europe, India, Japan, South Africa, MENA
出版日期: 2017年07月26日 內容資訊: 英文 214 Pages
簡介

本報告提供全球主要50家學名藥廠商公司簡介,活動,技術及近幾年的財務實際成果議論,並彙整M&A,新產品,展望,課題及計劃等發展評估,學名藥收益的預測 (主要18公司) 等資料。

第1章 調查概要

第2章 學名藥廠商前50大企業

  • 學名藥廠商前50大企業:收益·排行榜
  • 學名藥廠商前50大企業:收益分析
  • 學名藥廠商前50大企業的地區分佈
  • 調查範圍
  • 調查的複雜性

第3章 北美的主要學名藥廠商:活動·展望

  • 本章對象企業
  • 美國的主要學名藥廠商:財務實際成果概要
  • Mylan - 北美最大的學名藥廠商:企業概要
  • Pfizer - 研究開發意向型的主要醫藥品企業:企業概要
  • Abbott:企業概要
  • Apotex - 加拿大最大的製藥公司:企業概要
  • Endo Pharmaceuticals:企業概要
  • Valeant Pharmaceuticals:企業概要
  • Pharmascience - 加拿大的主要企業:企業概要
  • Mallinckrodt::企業概要
  • Akorn Pharmaceuticals:企業概要
  • Alvogen - 民間擁有的美國企業,熱門企業之1公司:企業概要
  • Impax Laboratories - 新加入企業:企業概要

第4章 歐洲的主要學名藥廠商:活動·展望

  • 本章對象企業
  • 歐洲的主要學名藥廠商:財務實際成果概要
  • CEE (中東歐) 市場是許多非專利競爭大企業的據點
  • Novartis (Sandoz) - 全球第2位的學名藥企業:概要
  • Sanofi:企業概要
  • Fresenius Kabi - 主要非專利點滴藥企業:企業概要
  • Pharmstandard - 俄羅斯最大的醫藥品廠商:企業概要
  • Gedeon 定睛看Richter - 更具前瞻性的匈牙利領導企業
  • 以Krka - 在70個以上國家活動的斯洛維尼亞的非專利巨大企業:企業概要
  • Stada Arzneimittel - 德國·中歐中佔有大市佔率的:企業概要
  • Perrigo:企業概要
  • Polpharma - 波蘭的學名藥powerhouse:企業概要
  • Chemo - 新加入企業:企業概要

第5章 印度的主要學名藥廠商:活動·展望

  • 本章對象企業
  • 印度:全球學名藥供應商
  • 印度的學名藥廠商前十大企業:財務實際成果概要
  • Sun Pharmaceutical - 印度的學名藥市場上領導者:企業概要
  • Dr. Reddy's Laboratories:企業概要
  • Lupin - 美國市場最成功的印度的學名藥企業:企業概要
  • Cipla - 在孟買設置據點的學名藥巨大企業:企業概要
  • Ranbaxy - 銷售到150個以上國家的印度第2大學名藥廠商:企業概要
  • Glenmark - 至今維繫學名藥成長的專業公司
  • Wockhardt - 美國·歐洲的學名藥市場佔有率擴大:企業概要
  • Cadila - 印度心血管市場上的領導企業:企業概要
  • Ipca Laboratories - 印度的醫藥品出口前十大企業之一:企業概要
  • Torrent Pharma - 建立全球學名藥市場上的地位:企業概要

第6章 其他地區的主要學名藥廠商:活動·展望

  • 本章對象企業
  • 其他地區的主要學名藥廠商:財務實際成果概要
  • 日本和巴西學名藥對全球學名藥市場特別重要
  • Teva Pharmaceutical Industries - 全球學名藥產業的領導企業:企業概要
  • EMS - 領導南美的學名藥市場:企業概要
  • Aspen Pharmacare - 持續擴大的南非巨大企業:企業概要
  • Nichi-Iko Pharmaceutical:企業概要
  • Abdi Ibrahim - 土耳其的主要醫藥品企業
  • Hypermarcas SA - 巴西的醫藥品·OTC巨大企業:企業概要
  • 在Eurofarma - 巴西中急速成長的學名藥企業:企業概要
  • Taro Pharmaceuticals - 第2大以色列醫藥品廠商:企業概要
  • 東和藥品 - 日本大企業之一:企業概要
  • 澤井製藥 - 據點設於大阪的學名藥領導者:企業概要

第7章 結論

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0217

The top 50 generic drug producers had combined revenues of $92bn in 2016. The top 10 generic drug producers have 62% share of the total revenue made by these top 50 companies. 30% of the top 50 generic drug producers fall under the RoW region. This figure reflects the increasing penetration of generics on a global scale with many pharmaceutical companies realising this industry as a primary source of revenue.

How this report will benefit you:

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 214-page report you will receive 74 tables and 71 figures - all unavailable elsewhere.

The 214-page report provides clear detailed insight into the top 50 generic drug producers. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • This report ranks the world's top 50 generic drug manufacturers according to their generic drug revenues in 2016.
  • Our report assesses the leading generic drug manufacturers worldwide. In general a company profile gives you the following information:
    • Discussion of activities, technologies and recent financial results
    • Assessment of developments - mergers and acquisitions (M&A), new products, outlooks, challenges and plans
    • Historical revenue ($) and CAGR (%) of top players
    • Forecasting of generic drug revenues to 2027 (for 18 leading companies).
  • This report discusses the factors that affect the industry:
    • M&A activity and related partnerships
    • Global and regional strategies - extending business reach
    • Competition from companies based in emerging national markets
    • Increasing specialisation by leading players, including big pharma companies
    • Increasing consolidation of the generics industry
    • Advances in production technologies, including difficult-to-make generics and biosimilars - important shifts and opportunities in the industry.
  • This report analyses the leading generic drug manufacturers in North America, including these companies:
    • Mylan
    • Pfizer
    • Abbott
    • Endo Pharmaceuticals
    • Valeant
  • This report analyses the leading generic drug manufacturers in Europe, including these companies:
    • Novartis (Sandoz)
    • Sanofi
    • Fresenius Kabi
    • Pharmstandard
    • Gedeon Richter
    • Stada Arzneimittel.
    • Perrigo
  • This report analyses the leading generic drug manufacturers in India, including these companies:
    • Sun Pharmaceutical Industries
    • Dr. Reddy's Laboratories
    • Lupin
    • Cipla
    • Aurobindo
    • Glenmark
    • Torrent Pharma
  • This report analyses the leading generic drug manufacturers in RoW, including these companies:
    • Teva Pharmaceutical Industries
    • EMS
    • Aspen Pharmacare
    • Nichi-Iko
    • Sawai Pharmaceutical
    • Taro Pharmaceutical
    • Abdi Ibrahim

Visiongain's study is intended for anyone requiring commercial analyses for the top generic drug manufacturers. You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top Generic Drug Producers Market Forecast 2017-2027: North America, Europe, India, Japan, South Africa, MENA.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Introduction to this Survey
  • 1.2. Main Report Findings
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methods of Research and Analysis
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Top 50 Generic Drug Manufacturers

  • 2.1. Top 50 Generic Drug Manufacturers: Revenues and Ranking, 2016
  • 2.2. Top 50 Generic Drug Companies: Revenue Analysis, 2016
  • 2.3. Top 50 Generic Drug Companies Regional Distribution, 2016
  • 2.4. Report Coverage
  • 2.5. Report Complexity
    • 2.5.1. Obtaining Data from Private Companies
    • 2.5.2. Financial Years Variability
    • 2.5.3. Generics Revenue Identification
    • 2.5.4. Defining Generics 1: Difference Between Biosimilars and Generics
    • 2.5.5. Defining Generics 2: ‘Super-Generics' and APIs
    • 2.5.6. Defining Generics 3: Rx and OTC

3. Top North American Generic Drug Manufacturers: Activities and Prospects, 2017-2027

  • 3.1. Companies Covered in this Chapter
  • 3.2. Leading North American Generic Drug Manufacturers: Financial Performance outline, 2016
  • 3.3. Mylan: Largest North American Manufacturer of Generic drugs, 2016
    • 3.3.1. Mylan Historical Performance and Financial Results Analysis, 2016
    • 3.3.2. Mylan Generic Drugs Revenue Forecast, 2017-2027
    • 3.3.3. First Class II Transdermal Approval Consolidates Mylan's Top Status in the US Market
    • 3.3.4. Mylan's European Portfolio is Diversifying
    • 3.3.5. Mylan's Generic Portfolio Remains the Company's Core Strength
    • 3.3.6. Mylan's Winning Acquisition Strategy
  • 3.4. Pfizer - The Leading Research-Based Pharmaceutical: Company Overview, 2016
    • 3.4.1. Pfizer Historical Performance and Financial Results Analysis, 2016
    • 3.4.2. Pfizer Generic Drugs Revenue Forecast, 2017-2027
    • 3.4.3. Pfizer Internationalization and Restructuring Strategy
    • 3.4.4. Pfizer's Acquisition of Hospira: Has it Boosted Revenue from Generics?
    • 3.4.5. Prospects for Pfizer's Generic Drugs Business
  • 3.5. Abbott: Company Overview, 2016
    • 3.5.1. Abbott Business Segments Performance
    • 3.5.2. Abbott Historical Performance and Financial Results Analysis, 2016
    • 3.5.3. Abbott Generic Drugs Revenue Forecast, 2017-2027
    • 3.5.4. Abbott's Acquisitions: Overview and Analysis, 2010-2016
    • 3.5.5. Abbott's Sale of its Overseas Branded Generic Business: Implications
    • 3.5.6. Future Prospects for Abbott Generic Drugs Business
  • 3.6. Apotex - The Largest Pharmaceutical Company in Canada: Company Overview, 2016
    • 3.6.1. Apotex Expansion to Europe and Beyond
    • 3.6.2. Apotex Announces $184 Million US Expansion Move for 2017
  • 3.7. Endo Pharmaceuticals: Company Overview, 2016
    • 3.7.1. Endo: Divests to Specialise in Generics
    • 3.7.2. Endo Reducing Presence on the South African Market
    • 3.7.3. Performance Analysis on Endo's US Generic Pharmaceuticals Segment
    • 3.7.4. Future Prospects for Endo Pharmaceuticals Generic Drugs Business
    • 3.7.5. Endo Generic Drugs Revenue Forecast, 2017-2027
    • 3.7.6. Par Pharmaceuticals: Merged with Endo Qualitest: Company Overview, 2016
    • 3.7.7. Par Pharmaceuticals' Acquisition of JPH Group Holdings
    • 3.7.8. Concentrated Generic Revenue Stream and Over 60 Generic Prescription Drugs
    • 3.7.9. Buy Out of Indian Ethics Bio Lab Demonstrates Par's Interest in Niche Products
  • 3.8. Valeant Pharmaceuticals: Company Overview, 2016
    • 3.8.1. Valeant: A Major Challenger in the Emerging Markets
    • 3.8.2. Valeant Generic Drugs Revenue Forecast, 2017-2027
  • 3.9. Pharmascience - Another Major Canadian Player: Company Overview, 2016
    • 3.9.1. Over 200 Generic Product Families
    • 3.9.2. Korean Venture Driving Diversification for Pharmascience
  • 3.10. Mallinckrodt: Company Overview, 2016
    • 3.10.1. Mallinckrodt Generics: Valuable Addition to the Company's Portfolio
    • 3.10.2. Reclassification of Methylphenidate ER Products: Effects on Mallinckrodt's Income
    • 3.10.3. What is Mallinckrodt's Advantage Against Strong Competition?
    • 3.10.4. Partnerships and Acquisitions: Crucial for Mallinckrodt's Rapid Expansion
  • 3.11. Akorn Pharmaceuticals: Company Overview, 2016
    • 3.11.1. Akorn Acquisition of Small Companies: A Strategic Shift Towards Broad Market Reach
    • 3.11.2. Akorn Strengthens its Position on the US Ophthalmology Market
  • 3.12. Alvogen is a Privately-Owned US Company and the One to Watch: Company Overview, 2016
    • 3.12.1. Alvogen Unique Business Model Proves Good Results
    • 3.12.2. Alvogen Target is to Become Top 10 Global Generic Player
  • 3.13. Impax Laboratories: A New Entrant on the Visiongain US List, Company Overview 2016
    • 3.13.1. Generic Revenues Decrease in 2016 for Impax

4. Top European Generic Drug Manufacturers: Activities and Prospects, 2017-2027

  • 4.1. Companies Covered in this Chapter
  • 4.2. Leading European Generic Drug Manufacturers: Financial Performance Outline, 2016
  • 4.3. CEE Markets Home to Many Big Generic Contenders
  • 4.4. Novartis (Sandoz) - the World's Second Largest Generic Pharmaceutical Company: Overview, 2016
    • 4.4.1. Novartis (Sandoz) Historical Performance and Financial Results Analysis, 2016
    • 4.4.2. Novartis (Sandoz) Generic Drugs Revenue Forecast, 2017-2027
    • 4.4.3. Novartis (Sandoz) Key Developments Analysis, 2017
    • 4.4.4. Emphasis on Complex, Differentiated Generics and Biosimilars
    • 4.4.5. Future Prospects for Novartis Generic Drugs Business
  • 4.5. Sanofi: Company Overview, 2016
    • 4.5.1. Sanofi Historical Performance and Financial Results Analysis, 2016
    • 4.5.2. Sanofi Generic Drugs Revenue Forecast, 2017-2027
    • 4.5.3. Sanofi Announces Intentions to Divest European Generics Business
    • 4.5.4. Future Prospects for Sanofi's Generic Drug Business
  • 4.6. Fresenius Kabi - Leading Generic Intravenous Drug Player: Company Overview, 2016
    • 4.6.1. Intra Venous Drugs: The Main Product Line for Fresenius Kabi
    • 4.6.2. Fresenius Kabi Will Continue to Expand
  • 4.7. Pharmstandard - The Largest Russian Pharmaceutical Manufacturer: Company Overview, 2016
    • 4.7.1. Acquisitions Strengthen Pharmstandard Manufacturing and Product Base
    • 4.7.2. Pharmstandard Benefits from Strong Organic Production Capacity
    • 4.7.3. Pharmstandard Generic Drugs Revenue Forecast, 2017-2027
  • 4.8. Gedeon Richter - Hungarian Leader Looking Further Afield: Company Overview, 2016
    • 4.8.1. Female Health and Fertility Segments Form Core Strengths for Gedeon Richter
    • 4.8.2. Specialisation Strategy for Further Growth
    • 4.8.3. A Pan-European Pharmaceutical Presence for the Future?
    • 4.8.4. Gedeon Richter Generic Drugs Revenue Forecast, 2017-2027
  • 4.9. Krka Pharmaceuticals- Slovenian Generic Giant Active in 70+ Countries: Company Overview, 2016
    • 4.9.1. Prescription Generics: Krka's Major Focus
    • 4.9.2. Eastern Europe is Still the Largest National Market for Krka
    • 4.9.3. Krka Generic Drugs Revenue Forecast, 2017-2027
  • 4.10. Stada Arzneimittel - Major Presence in Germany and Central Europe: Company Overview, 2016
    • 4.10.1. Germany is the Largest Market for Stada's Generics Segment
    • 4.10.2. Strong Product Development with Over 660 Product Launches in 2016
    • 4.10.3. Stada Arzneimittel Generic Drugs Revenue Forecast, 2017-2027
  • 4.11. Perrigo: Company Overview, 2016
    • 4.11.1. Perrigo Drives Generic Segment Growth through Acquisitions, but Will it be Acquired Itself?
    • 4.11.2. Rx Pharmaceuticals: Main Contributors to Perrigo's Revenue Stream
  • 4.12. Polpharma - Poland's Generic Powerhouse: Company Overview, 2016
    • 4.12.1. Polpharma's Continuous Product Portfolio Enlargement
    • 4.12.2. Strong Regional Presence in Poland, Russia and Kazakhstan
    • 4.12.3. Acquisition Increases Polpharma Dominance in the Polish Market
  • 4.13. Chemo: New Entrant on the Visiongain European Generics List, Company Overview 2016

5. Top Indian Generic Drug Manufacturers: Activities and Prospects, 2017-2027

  • 5.1. Companies Covered in This Chapter
  • 5.2. India: Generics Supplier to the World
  • 5.3. Top 10 Indian Generic Drug Manufacturers: Financial Performance Outline, 2016
  • 5.4. Sun Pharmaceutical - Leader in the Indian Generic Drug Market, Company Overview, 2016
    • 5.4.1. Sun Has a Leading Presence in the Generic Export Market
    • 5.4.2. Mega Acquisition of Ranbaxy to Enlarge Sun's Market Share
    • 5.4.3. Sun Pharmaceutical Generic Drugs Revenue Forecast, 2017-2027
  • 5.5. Dr. Reddy's Laboratories: Company Overview, 2016
    • 5.5.1. At the Forefront of the Indian Generic Boom: Dr. Reddy's Gerneric Revenue Approaching $2bn in 2016
    • 5.5.2. North America is the Largest Export Markets for Dr. Reddy's
    • 5.5.3. Dr. Reddy's Early Leadership in Biosimilar Antibodies
    • 5.5.4. Dr. Reddy's: Generic Drugs Revenue Forecast, 2017-2027
  • 5.6. Lupin - The Most Successful Indian Generic Firm in the US Market: Company Overview, 2016
    • 5.6.1. Lupin's Continuous Portfolio Growth and Focus on Complex Injectables
    • 5.6.2. Strong R&D Investment in New Delivery Systems and Original Products
    • 5.6.3. Lupin Generic Drugs Revenue Forecast, 2017-2027
  • 5.7. Cipla - Mumbai Based Generic Giant: Company Overview, 2016
    • 5.7.1. Cipla Targets a US Expansion Through Acquisitions
    • 5.7.2. Cipla's Leadership in Anti-Retroviral Drugs and Focus on Key Markets
    • 5.7.3. Chronic Disease: A Significant Target for Cipla
    • 5.7.4. Cipla Generic Drugs Revenue Forecast, 2017-2027
  • 5.8. Aurobindo - The Largest FDA APIs Supplier, Moved Into Original Drugs: Company Overview, 2016
    • 5.8.1. High-Margin Specialty Generics
    • 5.8.2. ANDA Filings and Approvals by Region, 2016
    • 5.8.3. CRAMS Opportunities
  • 5.9. Glenmark - Specialty Company Still Leveraging Generic Growth: Overview, 2016
    • 5.9.1. Generics Remain Part of Global Growth Strategy for Glenmark
    • 5.9.2. Glenmark Benefits from a Surge in the US and India
    • 5.9.3. Glenmark Generic Drugs Revenue Forecast, 2017-2027
  • 5.10. Wockhardt -Increasing Presence in US and Europe Generics Market: Company Overview, 2016
    • 5.10.1. US Market Growth in 2016
    • 5.10.2. Biosimilars, Novel Delivery Systems and Original Drugs Will Drive Growth for Wockhardt
  • 5.11. Cadila - Leader in Indian Cardiovascular Market: Company Overview, 2016
    • 5.11.1. Biochem Acquisition Boosts Cadila's Revenue
    • 5.11.2. Increasing Presence in the US Market
    • 5.11.3. Cadila: A Future Biosimilar Force?
  • 5.12. Ipca Laboratories - One of Top 10 Indian Pharma Exporters: Company Overview, 2016
    • 5.12.1. Fast Development Due to Niche Strategic Approach
  • 5.13. Torrent Pharma Establishes Itself on the Global Generics Market: Company Overview 2016
    • 5.13.1. Domestic and US Expansion Continued in 2016

6. Top Generic Drug Manufacturers from the Rest of the World: Activities and Prospects, 2017-2027

  • 6.1. Companies Covered in this Chapter
  • 6.2. Leading Rest of the World Generic Drug Manufacturers: Financial Performance Outline, 2016
  • 6.3. Japanese and Brazilian Generic Environment Particularly Significant to the Global Generic Drug Market
  • 6.4. Teva Pharmaceutical Industries: Company Overview of the World's Generic Industry Leader, 2016
    • 6.4.1. Teva Historical Performance and Financial Results Analysis, 2014-2016
    • 6.4.2. Teva Generic Drugs Revenue Forecast, 2017-2027
    • 6.4.3. Teva's Global Presence
    • 6.4.4. How did Teva Achieve its Success?
    • 6.4.5. Teva Operational Strategy: Focus on Cost Reduction
    • 6.4.6. The US Market Stagnates but Teva Sustains its Strong Penetration
    • 6.4.7. From Volume to Value Driven Strategy in the European Markets
    • 6.4.8. Teva Strengthens its Position in the Central Nervous System Market Through the Acquisition of Auspex Pharma
    • 6.4.9. Teva Acquires Actavis Consolidating Position as the Global Leader
      • 6.4.9.1. Actavis: Company History
  • 6.5. EMS - Leading the South American Generic Market: Company Overview, 2016
    • 6.5.1. First Brazilian Company to Export Generics to Europe
    • 6.5.2. EMS Has the Most Advanced Latin American R&D Base
  • 6.6. Aspen Pharmacare - South African Giant Continues to Expand: Company Overview, 2016
    • 6.6.1. Continuing Dominance in South Africa Generic Market
    • 6.6.2. Asia-Pacific and International Business Main Revenue Contributors in 2016
    • 6.6.3. Europe/CIS and Latin America: Another Major Growth Opportunity for Aspen
    • 6.6.4. Aspen Generic Drugs Revenue Forecast, 2017-2027
  • 6.7. Nichi-Iko: Company Overview, 2016
    • 6.7.1. More Than 900 Generic Products in Nichi-Iko Portfolio
    • 6.7.2. Nichi-Iko Acquires Sagent Pharmaceuticals
  • 6.8. Abdi Ibrahim: Turkey's Leading Pharmaceutical Company 2016
    • 6.8.1. Large Product Portfolio Helps to Sustain Market Position
    • 6.8.2. Abdi Ibrahim has a Vast International Scope
  • 6.9. Hypermarcas SA - Brazilian Pharmaceutical and OTC Giant: Company Overview, 2016
  • 6.10. Eurofarma - Rapidly-Growing Generics Power in Brazil: Company Overview, 2016
    • 6.10.1. Nine Diversified Business Divisions
    • 6.10.2. M&A Extending Latin American Reach for Eurofarma
  • 6.11. Taro Pharmaceuticals - The Second Largest Israeli Pharmaceutical Manufacturer: Company Overview, 2016
    • 6.11.1. Taro Acquires Zalicus Pharmaceutical in 2015
  • 6.12. Towa Pharmaceuticals - Another Big Japanese Player: Company Overview, 2016
    • 6.12.1. Large Number of Generic Products in Towa's Portfolio
    • 6.12.2. Towa's Broad and Expanding Production Capacity
  • 6.13. Sawai Pharmaceuticals - Osaka-Based Generic Leader: Company Overview, 2016
    • 6.13.1. Annual Manufacturing Ambitions to Reach 15 Billion Tablets in 2017
    • 6.13.2. Cardiovascular Drugs are the Most Significant Therapeutic Area for Sawai
    • 6.13.3. M&A Boosts Sawai's R&D

7. Conclusions

  • 7.1. Companies' Growth Strategies
  • 7.2. Why are Big Pharma Companies Targeting Generics?
  • 7.3. Teva's Acquisition of Actavis: The Latest Major Consolidation for the Generic Drug Industry
  • 7.4. Big Pharma Business Models Evolve
  • 7.5. Biosimilars Will Have a Transformative Effect on Both Generic and Originator Drug Companies
  • 7.6. Complex Generics with High Entry Barriers Continue to Increase in Importance
  • 7.7. Future Trends for Generic Drug Producers - What's Possible?
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Associated Visiongain Reports
  • Appendix C
  • Visiongain report evaluation form

List of Figures

  • Figure 2.1: Top 50 Generic Drug Manufacturers: Revenues ($m), 2016
  • Figure 2.2: Generic Drug Manufacturers: Revenue ($m) Comparison by Group Rank, 2016
  • Figure 2.3: Top 50 Generic Drug Manufacturers: Market Share (%) Amongst the Top 50 Companies According to Group Rank, 2016
  • Figure 2.4: Top 10 Generic Drug Manufacturers: Market Share (%) Among the Top 50 Companies, 2016
  • Figure 2.5: Regional Balance Among the Top 50 Generic Drug Manufacturers, 2016
  • Figure 2.6: Biosimilars and Generics: Overview, 2017
  • Figure 3.1: Top 10 North American Generic Manufacturers: Revenues ($m), 2016
  • Figure 3.2: Mylan: Historical Generic Drugs Revenue Estimate($m), AGR (%), 2012-2016
  • Figure 3.3: Mylan: Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 3.4: Mylan: Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 3.5: Pfizer: Historical Generic Drugs Revenue Estimate($m), AGR (%), 2012-2016
  • Figure 3.6: Pfizer: Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 3.7: Pfizer: Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 3.8: Abbott: Historical Generic Drugs Revenue Estimate($m), AGR (%), 2012-2016
  • Figure 3.9: Abbott: Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 3.10: Abbott: Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 3.11: Endo: Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 3.12: Endo: Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 3.13: Valeant: Revenue Breakdown by Business Segment, 2016
  • Figure 3.14: Valeant: Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 3.15: Valeant: Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 3.16: Akorn's Key Acquisition: Reasons Overview
  • Figure 4.1: Top 10 European Generic Manufacturers: Revenues ($m), 2016
  • Figure 4.2: Novartis: Revenue Breakdown by Business Segment, 2016
  • Figure 4.3: Novartis (Sandoz): Historical Generic Drugs Revenues ($m), AGR (%), 2012-2016
  • Figure 4.4: Novartis (Sandoz): Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 4.5: Novartis (Sandoz): Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 4.6: Sanofi: Historical Generic Drugs Revenues ($m), AGR (%), 2012-2016
  • Figure 4.7: Sanofi: Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 4.8: Sanofi: Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 4.9: Pharmstandard: Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 4.10: Pharmstandard: Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 4.11: Gedeon Richter: Revenue Breakdown by Therapeutic Segment, 2016
  • Figure 4.12: Gedeon Richter: Geographical Revenue Breakdown, 2016
  • Figure 4.13: Gedeon Richter: Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 4.14: Gedeon Richter: Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 4.15: Krka Pharmaceuticals: Revenue Breakdown by Business Segment, 2016
  • Figure 4.16: Krka Pharmaceuticals: Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 4.17: Krka Pharmaceuticals: Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 4.18: Stada: Revenue Breakdown (%) by Business Segment, 2016
  • Figure 4.19: Stada: Top 8 Generic Markets by Revenue, 2016
  • Figure 4.20: Stada Arzneimittel: Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 4.21: Stada Arzneimittel: Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 5.1: Top Indian Generic Manufacturers: Revenues ($m), 2016
  • Figure 5.3: Sun Pharmaceutical: Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 5.4: Sun Pharmaceutical: Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 5.5: Dr. Reddy's: Revenue Breakdown by Business Segment, 2016
  • Figure 5.6: Dr. Reddy's: Revenue Breakdown by Region, 2016
  • Figure 5.7: Dr. Reddy's: Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 5.8: Dr. Reddy's: Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 5.9: Lupin: Revenue Breakdown by Markets, 2016
  • Figure 5.10: Lupin: Revenue Breakdown by Therapeutic Area, 2016
  • Figure 5.11: Lupin: Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 5.12: Lupin: Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 5.13: Cipla: Revenue Breakdown by Region, 2016
  • Figure 5.14: Cipla: Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 5.15: Cipla: Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 5.16: Glenmark: Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 5.17: Glenmark: Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 5.18: Wockhardt: Revenue Breakdown by Region, 2016
  • Figure 5.19: Ipca: Revenue Breakdown by Region, 2016
  • Figure 6.1: Top 10 Rest of the World Generic Manufacturers: Revenues ($m), 2016
  • Figure 6.2: Teva: Revenue Breakdown by Region, 2016
  • Figure 6.3: Teva: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014
  • Figure 6.4: Teva: Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 6.5: Teva: Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 6.6: Teva: Revenue Breakdown by Region, 2016
  • Figure 6.7: Teva: Annual Generic Revenue Change (%) in EU Countries, 2015-2016
  • Figure 6.8: Aspen: Revenue Breakdown (%) by Region, 2016
  • Figure 6.9: Aspen: Generic Drugs Revenue Forecast ($m), 2017-2027
  • Figure 6.10: Aspen: Generic Drugs AGR Forecast (%), 2017-2027
  • Figure 7.1: Top 10 Generic Drug Manufacturers: Market Share (%) Among the Top 50 Companies, 2016
  • Figure 7.2: Regional Balance Among the Top 50 Generic Drug Manufacturers, 2016

List of Tables

  • Table 2.1: Top 50 Generic Drug Manufacturers: Global Rank 1-25, Country and Revenues from Generics ($m), 2016
  • Table 2.2: Top 50 Generic Drug Manufacturers: Global Rank 26-50, Country and Revenues from Generics ($m), 2016
  • Table 2.3: Top 50 Generic Drug Manufacturers: Revenue ($m) and Market Share (%) According to Group Rank, 2016
  • Table 2.4: Regional Distribution of the Top 50 Companies, 2016
  • Table 3.1: Top 10 North American Generic Drug Manufacturers: Revenues ($m) and Ranking, 2016
  • Table 3.2: Mylan: Company Overview, 2016
  • Table 3.3: Mylan: Historical Generic Drugs Revenue Estimate($m), AGR (%), 2012-2016
  • Table 3.4: Mylan: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 3.5: Pfizer: Company Overview, 2016
  • Table 3.6: Pfizer: Historical Generic Drugs Revenue Estimate ($m), AGR (%), 2012-2016
  • Table 3.7: Pfizer: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 3.8: Abbott: Company Overview, 2016
  • Table 3.9: Abbott: Historical Generic Drugs Revenue Estimate ($m), AGR (%), 2012-2016
  • Table 3.10: Abbott: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 3.11: Apotex: Company Overview, 2016
  • Table 3.12: Endo: Company Overview, 2016
  • Table 3.13: Endo: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 3.14: Valeant: Company Overview, 2016
  • Table 3.15: Valeant: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 3.16: Pharmascience: Company Overview, 2016
  • Table 3.17: Mallinckrodt: Company Overview, 2016
  • Table 3.18: Akorn Pharmaceuticals: Company Overview, 2016
  • Table 3.19: Alvogen Pharmaceuticals: Company Overview, 2016
  • Table 3.20: Impax Laboratories: Company Overview, 2016
  • Table 4.1: Top European Generic Manufacturers: Revenues ($m), 2016
  • Table 4.2: Novartis (Sandoz): Company Overview, 2016
  • Table 4.3: Novartis (Sandoz): Historical Generic Drugs Revenues ($m), AGR (%), 2012-2016
  • Table 4.4: Novartis (Sandoz): Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 4.5: Sanofi: Company Overview, 2016
  • Table 4.6: Sanofi: Historical Generic Drugs Revenues ($m), AGR (%), 2012-2016
  • Table 4.7: Sanofi: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 4.8: Fresnius Kabi: Company Overview, 2016
  • Table 4.9: Pharmstandard: Company Overview, 2016
  • Table 4.10: Pharmstandard: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 4.11: Gedeon Richter: Company Overview, 2016
  • Table 4.12: Gedeon Richter: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 4.13: Krka Pharmaceuticals Company Overview, 2016
  • Table 4.14: Krka Pharmaceuticals: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 4.15: Stada Arzneimittel Company Overview, 2016
  • Table 4.16: Stada Arzneimittel Pharmaceuticals: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 4.17: Perrigo: Company Overview, 2016
  • Table 4.18: Polpharma: Company Overview, 2016
  • Table 4.19: Chemo: Company Overview, 2016
  • Table 5.1: Top 10 Indian Generic Manufacturers: Revenues($m) and Ranking, 2016
  • Table 5.2: Sun Pharmaceutical: Company Overview, 2016
  • Table 5.3: Sun Pharmaceutical: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 5.4: Dr. Reddy's: Company Overview, 2016
  • Table 5.5: Dr. Reddy's: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 5.6: Lupin: Company Overview, 2016
  • Table 5.7: Lupin: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 5.8: Cipla: Company Overview, 2016
  • Table 5.9: Cipla: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 5.10: Aurobindo: Company Overview, 2016
  • Table 5.11: Aurobindo: ANDA Filings and Approvals by Region, 2016
  • Table 5.12: Glenmark: Company Overview, 2016
  • Table 5.13: Glenmark: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 5.14: Wockhardt: Company Overview, 2016
  • Table 5.15: Cadila: Company Overview, 2016
  • Table 5.16: Ipca: Company Overview, 2016
  • Table 5.17: Torrent Pharma: Company Overview, 2016
  • Table 6.1: Top 10 Rest of the World Generic Drug Manufacturers, Revenues ($m) and Ranking, 2016
  • Table 6.2: Teva: Company Overview, 2016
  • Table 6.3: Teva: Historical Generic Drugs Revenues ($m), AGR (%), 2014-2016
  • Table 6.4: Teva: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 6.5: EMS: Company Overview, 2016
  • Table 6.6: Aspen Pharmacare: Company Overview, 2016
  • Table 6.7: Aspen: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 6.8: Nichi-Iko: Company Overview, 2016
  • Table 6.9: Abdi Ibrahim: Company Overview, 2016
  • Table 6.10: Hypermarcas: Company Overview, 2016
  • Table 6.11: Eurofarma: Company Overview, 2016
  • Table 6.12: Taro Pharmaceutical: Company Overview, 2016
  • Table 6.13: Towa Pharmaceutical: Company Overview, 2016
  • Table 6.14: Sawai Pharmaceutical: Company Overview, 2016

Companies Listed

  • AbbVie
  • Abdi Ibrahim
  • Abrika Pharmaceuticals
  • Ache
  • Actavis
  • Active Pharma
  • Adcock Ingram
  • Advanced Vision Research
  • Aegera
  • Afrexa Life Sciences
  • Agouron Pharmaceuticals
  • Akorn Pharmaceuticals
  • Akrikhin
  • Alcon
  • Allergan
  • Alpharma
  • Alvogen
  • AmerisourceBergen
  • Amide
  • Amneal Pharmaceuticals
  • AMS
  • APL Holdings Limited
  • ApoPharma
  • Apotex
  • Apotex Fermentation
  • APP Pharmaceuticals
  • Aprogen
  • Arrow Group
  • Asahi Kasei Pharma Corporation
  • Ascent Pharmahealth
  • ASKA Pharmaceutical
  • Aspen
  • Aspen Pharmacare
  • Aspen Trading
  • AstraZeneca
  • Auden McKenzie
  • Aurigene Discovery Technologies
  • Auro Pharma
  • Aurobindo
  • Balkanpharma
  • Barr Pharmaceuticals
  • Bausch and Lomb Holdings
  • Bayer
  • Bayer Yakuhin
  • BeiKang Pharmaceutical
  • Bever
  • Biocad Holding
  • Bioniche Pharma
  • Biovena
  • Boca Pharmacal
  • Boehringer Ingelheim
  • Brainfarma Industria e Farmaceutica
  • Bremer Pharma
  • Bunker and Delta
  • Cadila Healthcare
  • Cardinal Health
  • Cenova Pharma
  • CFR Pharmaceuticals
  • Chattem Chemicals
  • Chemo Group
  • Chimpharm
  • Chiron Corporation
  • Chirotech Technology
  • CIBA VISION
  • Cipla
  • CNS Therapeutics
  • Colotech
  • Cosmed Industria de Cosmeticos e Medicamentos S.A.
  • D. Searle & Company
  • Dabur Pharma
  • DACA Pharmaceuticals
  • Daichi Kasei
  • Dialfor Health
  • DKSH
  • Dr. Reddy's Laboratories
  • Dream Pharma
  • Dusa Pharmaceuticals
  • EBEWE Pharma
  • Elan Pharmaceuticals
  • Elder Pharmaceuticals
  • Emcure
  • Emergent Biosolutions
  • Emploi Quebec
  • EMS
  • Endo
  • Eon Labs
  • Ethics Bio Lab
  • Eurofarma
  • European Medicines Agency (EMA)
  • Facet Biotech
  • Fako
  • Fenwal
  • Filaxis
  • Fougera Pharmaceuticals
  • Fresenius Kabi
  • Fuso Pharmaceutical Industries
  • Gangene Corp
  • Gedeon Richter
  • Generic Health
  • Generic Pharmaceutical Association (GPhA)
  • Genfar S.A.
  • Genzyme
  • Germa Pharm
  • GlaxoSmithKline (GSK)
  • Glenmark
  • Globalpharma
  • Golden Cross Pharma
  • Greenstone
  • Handok
  • HealthTronics
  • Helvepharm
  • Herbapol Pruszkow
  • Hexa
  • Hikma
  • Hi-Tech Pharmacal
  • Hospira
  • Hypermarcas
  • IDEV Technologies
  • Ikaria
  • Impax Laboratories
  • Innopharma
  • Inspire Pharmaceuticals
  • Investissement Quebec
  • Ipca Laboratories
  • J-DOLPH Pharmaceutical
  • Johnson & Johnson
  • JPH Group Holdings
  • Kanghong Sagen Pharmaceuticals
  • Keri Pharma
  • Kilitch Drugs
  • Kolmar Holdings
  • Krka
  • Kunwha Pharmaceuticals
  • Kyowa Pharmaceuticals
  • Labesfal
  • Laboratorio Sanderson
  • Laboratorios Gautier
  • Laboratorios Grin
  • Laboratorios Kendrick
  • Labormed Pharma
  • Leek
  • Lekko
  • Les Laboratoires Servier SAS
  • Lotus Pharmaceuticals
  • Lupin
  • mAbxience
  • Madaus
  • Mallinckrodt
  • Maruko Pharmaceutical
  • Masterlek
  • McKesson Drug Company
  • Mechnikov Biomed
  • Mediate Specialities
  • Medina
  • Medisa Shinyaku
  • Medley Industria Farmaceutica
  • Meiji Seika Pharma
  • Merck & Co
  • Microdose
  • Mitani Sangyo
  • Mitsubishi Tanabe Pharma
  • MJ Pharma
  • Multicare
  • Mylan Laboratories
  • Nanomi B.V
  • National Druggists
  • NBZ Pharma Limited
  • Negma
  • Nichi-Iko
  • Nichi-Iko Pharma Tech
  • Nicox
  • Nippon Chemipher
  • Nippon Kayaku
  • NIXS Corporation
  • Novartis
  • Nycomed
  • Oak Pharmaceuticals
  • OctoPlus
  • Omega Laboratories Limited
  • Onset Dermatologics
  • Onyx
  • Oriel Therapeutics
  • Orion
  • Paladin Labs
  • Par Pharmaceutical
  • Parke-Davis
  • Pendopharm
  • Perrigo Company
  • Pfizer
  • PGT Healthcare
  • Pharma Avalanche
  • Pharmacin
  • Pharmapark
  • Pharmascience
  • Pharmascience Korea
  • PharmaSwiss
  • Pharmstandard
  • Pharmstandard Biotec
  • Phlox Pharma
  • Pinewood Laboratories
  • Piramal Healthcare Solutions
  • Polfa Warszawa
  • Polpharma
  • Pradeep Drug Company
  • Promius Pharma
  • Pymepharco
  • Qalitest
  • Questcor
  • Ranbaxy Laboratories
  • Ranbaxy Life Sciences Research
  • Ratiopharm
  • Ribbon
  • Richter-Helm
  • Roche
  • Romark Laboratories
  • Sabex
  • Sagent Acquisition Corp
  • Salix Pharmaceuticals
  • Sandoz
  • Sanofi
  • Sanofi Pasteur
  • Sawai Pharmaceuticals
  • Schein Pharmaceutical
  • Sekisui Medical
  • Shantha Biotechnics
  • Silom Medical Company
  • Sindan
  • Solus Pharmaceuticals
  • Solvay Pharmaceuticals
  • Somar
  • Specifar Pharmaceuticals S.A.
  • SPIL de Mexico
  • Spirig Pharma
  • Stada Arzneimittel
  • STARLIMS
  • Sun Pharmaceutical
  • Swisse Wellness
  • Taiyo Cephalon
  • Taro
  • Technologies Inc
  • Teikoku Medix
  • Terapia S.A.
  • Teva Pharmaceutical Industries
  • The European Generic Medicines Association (EGA)
  • TKS Pharmaceutical
  • Torrent Pharmaceuticals
  • Towa
  • UDL Laboratories
  • United Research Laboratories
  • URL Pharma
  • US Food and Drug Administration (FDA)
  • Uteron Pharma S.A.
  • Valeant
  • Velefarm
  • Veropharm
  • VersaPharm Incorporated
  • Vindexpharm
  • VPI Holdings Corp
  • Warner Chilcott
  • Warner Lambert
  • Watson Pharmaceuticals
  • Winthrop
  • Wockhardt
  • Wyeth
  • World Health Organisation (WHO)
  • Yakuhan Pharmaceuticals
  • ZAO Ranbaxy
  • Zao Sun Pharma
  • Zhejiang Chiral Medicine Chemicals Company
  • ZiO Zdorovje
  • Zoetis
  • Zydus Pharmaceuticals
  • Zydus Wellness
Back to Top